A December 2006 review of clinical studies on chromium picolinate, published in Diabetes Technology & Therapeutics, confirmed that chromium picolinate improves blood glucose control and lipid levels in people with type 2 diabetes.
Because chromium picolinate is the form of supplemental chromium best absorbed by the body, the review focused on that form alone. Fifteen clinical studies were analyzed, totaling 1,690 people with diabetes. Chromium picolinate dosages ranged from 200 to 1000 mcg per day, for a period of one week to ten months.
Although glycemic control varied by trial, all 15 trials showed improvements in at least one of the following areas: blood glucose control, insulin levels, cholesterol levels, triglyceride levels, or requirement for hypoglycemic medication. The review concluded that chromium picolinate supplementation, especially at higher doses, may help control symptoms of diabetes.